Hennion & Walsh Asset Management, Inc. Agios Pharmaceuticals, Inc. Transaction History

Hennion & Walsh Asset Management, Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 20, 2023	SELL	$21.74 - $30.93 $16,783 - $23,877	-772 Reduced 3.31%	22,525 $517,000
Q4 2022 Jan 12, 2023	BUY	$24.81 - $31.52 $73,040 - $92,794	2,944 Added 14.46%	23,297 $654,000
Q3 2022 Nov 14, 2022	SELL	$19.51 - $34.14 $5,501 - $9,627	-282 Reduced 1.37%	20,353 $576,000
Q2 2022 Jul 19, 2022	SELL	$17.06 - $31.42 $5,237 - $9,645	-307 Reduced 1.47%	20,635 $457,000
Q1 2022 Apr 26, 2022	BUY	$26.68 - $34.81 $11,392 - $14,863	427 Added 2.08%	20,942 $610,000
Q4 2021 Feb 14, 2022	BUY	$29.58 - $49.78 $37,951 - $63,867	1,283 Added 6.67%	20,515 $674,000
Q3 2021 Nov 12, 2021	BUY	$41.92 - $58.18 $276,085 - $383,173	6,586 Added 52.08%	19,232 $888,000
Q2 2021 Aug 13, 2021	SELL	$52.06 - $61.27 $142,384 - $167,573	-2,735 Reduced 17.78%	12,646 $697,000
Q1 2021 May 17, 2021	BUY	$44.23 - $57.5 $680,301 - $884,407	15,381 New	15,381 $794,000

232

58.1M

403K

469K

Ticker AGIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,818,000
Market Cap $3.24B
Description
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and ...

Get notified when there are updates to the investment portfolio of Hennion & Walsh Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Hennion & Walsh Asset Management, Inc. with notifications on news.